Activated glial proinflammatory cytokine production pathways (null)

Activated glial proinflammatory cytokine production pathways Overview

Activated glial proinflammatory cytokine production pathways refer to the complex signaling cascades within microglia and astrocytes that lead to the synthesis and secretion of inflammatory mediators such as TNF-alpha, IL-1beta, and IL-6 [PubMed: 22531024]. In the central nervous system, glia transition from a homeostatic state to an activated proinflammatory phenotype in response to injury, infection, or protein aggregates like amyloid-beta. This process is mediated by various receptors, including Toll-like receptors (TLRs) and purinergic receptors, which trigger downstream effectors like NF-kappaB and the NLRP3 inflammasome [PubMed: 24321450]. Chronic activation of these pathways is a hallmark of neurodegenerative diseases, chronic pain, and psychiatric disorders, contributing to neuronal damage and disease progression. Therapeutic strategies aim to modulate these pathways using small molecules like Ibudilast or minocycline to dampen neuroinflammation without compromising the essential protective roles of glial cells [PubMed: 18448052]. By shifting the glial population toward a more anti-inflammatory or homeostatic state, these therapies seek to slow the progression of conditions like Alzheimer's disease and ALS.

Mechanism of Action

Drugs targeting these pathways typically act by inhibiting specific signaling nodes such as phosphodiesterases (e.g., Ibudilast), antagonizing Toll-like receptors (e.g., TLR4), or suppressing the activation of transcription factors like NF-kappaB and kinases like p38 MAPK to reduce the synthesis and release of proinflammatory cytokines like TNF-alpha and IL-1beta [PubMed: 18448052, 22531024].

Biological Functions

Safety Considerations

Interacting Drugs

Associated Biomarkers